Elsevier Inc.

SHERPA: Unknown

People

  1. Wolden
    Wolden
  2. Basu
    Basu
  3. Cheung
    Cheung
  4. Kushner
    Kushner
  5. Modak
    Modak
  6. La Quaglia
    La Quaglia
  7. Calder
    Calder
  8. Dela Cruz
    Dela Cruz
  9. Friedman
    Friedman
  10. Ibanez Sanchez
    Ibanez Sanchez

Groups

  1. Center for Hematologic Malignancies (5)
  2. Neuroblastoma Service (5)
  3. Pediatrics, Department of (5)
  4. Pediatric Leukemia (4)
  5. Radiation Oncology, Department of (4)
  6. Survivorship Research (4)
  7. Tow Center for Developmental Oncology (TCDO) (4)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (3)
  9. GSK Faculty (3)
  10. Surgery (2)
Search Within
  1. "Stephen Roberts"
Formats
  1. Meeting Abstract (3)
  2. Book Section (1)
  3. Journal Article (1)
Groups
  1. Center for Hematologic Malignancies (5)
  2. Neuroblastoma Service (5)
  3. Pediatrics, Department of (5)
  4. Pediatric Leukemia (4)
  5. Radiation Oncology, Department of (4)
  6. Survivorship Research (4)

More Groups

People
  1. Stephen Roberts (5)
  2. Suzanne Wolden (4)
  3. Brian Kushner (3)
  4. Ellen Basu (3)
  5. Nai-Kong Cheung (3)
  6. Shakeel Modak (3)

More People

Years
  1. 2020 (1)
  2. 2019 (1)
  3. 2017 (1)
  4. 2016 (1)
  5. 2015 (1)
Publications
  1. International Journal of Radiation Oncology, Biology, Physics (3)
  2. Clinical Radiation Oncology. 4th ed (1)
  3. European Journal of Cancer (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TPX-0005 (Repotrectinib), a next-generation ALK/ROS1/NTRK1-3 inhibitor, has potent antiproliferative and anti-tumor activity as monotherapy and in combination with chemotherapy in neuroblastoma cell lines and pediatric patient derived xenograft models
    Meeting Abstract

    O'Donohue, T.; Ibáñez, G.; Mauguen, A.; Siddiquee, A.; Rosales, N.; Calder, P.; Ndengu, A.; Roberts, S.; Dela Cruz, F.; Kung, A.
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • Reduced-dose radiation therapy to the primary site is effective for high-risk neuroblastoma: Results from a prospective trial
    Journal Article

    Casey, D. L.; Kushner, B. H.; Cheung, N. K. V.; Modak, S.; Basu, E. M.; Roberts, S. S.; LaQuaglia, M. P.; Wolden, S. L.
    International Journal of Radiation Oncology, Biology, Physics (2019)

    Fulltext@MSK | Save
  • Local control with reduced-dose radiation therapy for high-risk neuroblastoma: Results from a prospective trial
    Meeting Abstract

    Casey, D. L.; Kushner, B.; Cheung, N. K.; Modak, S.; La Quaglia, M. P.; Basu, E.; Roberts, S.; Wolden, S. L.
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save
  • Neuroblastoma
    Book Section

    Wolden, S. L.; Roberts, S. S.
    In Gunderson, L. L.; Tepper, J. E. (Eds.) Clinical Radiation Oncology. 4th ed (2016)

    Fulltext@MSK | Save
  • Predisposing factors for short stature in long-term survivors of high-risk neuroblastoma
    Meeting Abstract

    Yang, J. C.; Friedman, D. N.; Woo, K. M.; Kushner, B. H.; Cheung, N. K. V.; Modak, S.; Roberts, S. S.; Basu, E. M.; Wolden, S. L.
    International Journal of Radiation Oncology, Biology, Physics (2015)

    Fulltext@MSK | Save